XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Short Interest Down 55.2% in August

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the recipient of a significant drop in short interest in August. As of August 14th, there was short interest totaling 10,999 shares, a drop of 55.2% from the July 30th total of 24,556 shares. Approximately 0.7% of the company’s stock are sold short. Based on an average trading volume of 5,965 shares, the days-to-cover ratio is currently 1.8 days.

XTL Biopharmaceuticals Price Performance

XTL Biopharmaceuticals stock opened at $2.47 on Friday. The company has a market capitalization of $5.43 million, a price-to-earnings ratio of -3.86 and a beta of 1.46. XTL Biopharmaceuticals has a one year low of $2.01 and a one year high of $10.28. The company’s fifty day moving average price is $2.79 and its two-hundred day moving average price is $2.73.

XTL Biopharmaceuticals (NASDAQ:XTLB) last released its quarterly earnings results on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) EPS for the quarter. The firm had revenue of ($0.26) million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.